TITLE

Once-daily treatment for overactive bladder

PUB. DATE
July 2008
SOURCE
British Journal of Hospital Medicine (17508460);Jul2008, Vol. 69 Issue 7, p377
SOURCE TYPE
Academic Journal
DOC. TYPE
Product Review
ABSTRACT
The article evaluates the Toviaz medicine from Pfizer.
ACCESSION #
33319444

 

Related Articles

  • Pfizer obtains complete response letter for anxiety disorder drug.  // PharmaWatch: CNS;Feb2010, Vol. 9 Issue 2, p11 

    No abstract available.

  • Ben-Gay: A warm, glowing endorsement. Moore, M.H. // Adweek Western Edition;8/14/95, Vol. 45 Issue 33, p31 

    Features the television commercial of Pfizer's Ultra-Strength Ben-Gay pain-relieving rub. Agency which created the advertisement; Theme; Use of thermographic photography.

  • Pfizer takes action against fake Lipitor. Dickinson, James G. // Medical Marketing & Media;Jul2003, Vol. 38 Issue 7, p22 

    Reports on the decision of pharmaceutical company Pfizer to take legal action against the distribution of counterfeit lots of its cholesterol-lowering drug Lipitor. Filing of punitive and statutory damages drug distributors Med-Pro and Albers Medical Distributors.

  • THERAPEUTIC FOCUS: HEUMATOLOGY.  // Medical Marketing & Media;Jun2011, Vol. 46 Issue 6, p43 

    A chart is presented that lists the top 40 rheumatology products for 2010 from different companies, including Celebrex from Pfizer Inc., Clobetasol propionate from Generic Inc., and Actemra from Genentech Inc.

  • 72 deaths reported from Zoloft overdoses. Dickinson, James G. // Medical Marketing & Media;Apr2001, Vol. 36 Issue 4, p34 

    Reports on the labeling revision of the antidepressant Zoloft of Pfizer Inc. in the U.S.

  • Long-Awaited Torcetrapib Will Not Be Released, Too Risky. Elliott, William T. // Internal Medicine Alert;5/15/2007, Vol. 29 Issue 9, p1 

    The article reports on the decision of Pfizer to discontinue the development of torcetrapib, a cholesteryl ester transfer protein (CETP) inhibitor that has been in development for about 15 years, following a trial which showed an increase in death from all causes associated with the drug.

  • Pfizer Places Zoloft's $50 Mil. Biz in Review. McMains, Andrew // Adweek Eastern Edition;1/31/2000, Vol. 41 Issue 5, p6 

    Reports on Pfizer Inc.'s placement of the advertising account for the antidepressant drug Zoloft in review. Estimated billings; Pfizer's plans in advertising the drug; Worldwide sales of the drug in 1998.

  • Pfizer figuring out OTC possibilities for Lipitor. Arnold, Matthew // Medical Marketing & Media;Sep2011, Vol. 46 Issue 9, p12 

    The article reports on the move of Pfizer Inc. in the U.S. to shift Lipitor into over-the-counter (OTC) that could help the company recover some of its losses.

  • Pfizer to discontinue ProMeris.  // DVM: The Newsmagazine of Veterinary Medicine;Jun2011, Vol. 42 Issue 6, p40 

    The article reports on the decision of New Jersey-based Pfizer Inc. to discontinue the distribution of ProMeris, a topical veterinary flea-and-tick treatment for dogs and cats, in 2011.

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics